Newsletters

[Clinical Cancer Research] In real-world cohorts, loss of SPEN function across genomic, transcriptomic, and protein levels is associated with reduced benefit from androgen receptor pathway inhibitors therapy in metastatic prostate cancer.

[Nature] Scientists described a novel therapeutic modality, domain-alteration chimeras, that rewire endogenous protein complexes by enforcing non-native domain–domain interactions.

[Clarity Pharmaceuticals (PR Newswire)] Clarity Pharmaceuticals announced that the US FDA granted ⁶⁴Cu-SAR-bisPSMA Breakthrough Therapy designation for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected recurrence based on elevated serum prostate-specific antigen level.

[International Immunopharmacology] Researchers investigate the expression profile of apolipoprotein C1 (APOC1) in the prostate cancer microenvironment and elucidated its mechanistic role in modulating macrophage polarization to promote tumor progression.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers identified EZH2 as a posttranslational suppressor of pyroptosis through direct methylation of GSDMD. They revealed that EZH2 inhibition triggered GSDMD-dependent pyroptosis in prostate cancer cells.

[Cell Reports Medicine] Researchers elucidated the molecular mechanism by which exportin 5 (XPO5) promotes prostate cancer (PCa) progression and developed the small-molecule degrader targeting XPO5 for the targeted treatment of PCa.

[Cell Death & Disease] The authors demonstrated that acquired resistance to the CDK4/6 inhibitor ribociclib in prostate cancer cells is driven by enhanced mitochondrial metabolic activity and increased dependence on fatty acid β-oxidation for energy production through the TCA cycle.

[Nature Communications] Scientists showed that prostate cancer cells metabolically adapt to the bone microenvironment by utilizing bone-cell-derived lactate as an alternative nutrient source.

[Critical Reviews in Oncology/Hematology] The authors synthesize recent mechanistic insights to provide a conceptual framework of the tumor-associated macrophage-driven metastatic cascade.

[Natera, Inc.] Natera, Inc. announced that it has entered into a clinical collaboration agreement with Incyte for a new phase II study in colorectal cancer to evaluate INCA33890, Incyte’s investigational bispecific immunotherapy.

[University of Texas MD Anderson Cancer Center] Susan Bullman, Ph.D., associate professor of Immunology and Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2027 Mary Beth Maddox Award and Lectureship from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

[University of Houston] University of Houston Associate Professor Melissa Zastrow has been awarded a $2.19 million National Institutes of Health grant to uncover how dietary metals like zinc and iron alter the human gut microbiome and potentially trigger gastrointestinal disease.